Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

Oral Abstract Session
© 2025 American Society of Clinical Oncology (ASCO).
Meeting: 2025 ASCO Annual Meeting
Presenter: Martin Wermke, University Hospital Carl Gustav Carus, Dresden, Germany
Session: Developmental Therapeutics—Immunotherapy
Date: May 31, 2025
Abstract Number: 2508
Disclosures: View Disclosures

Disclaimer

This content was selected by and is provided to you courtesy of Immatics.

ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission.

This presentation does not necessarily represent a balanced view or full discussion of any given subject. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. The authors, editors, and ASCO are not responsible for errors or omissions in translations. The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.

Immatics Final logo_5472x1872

Selected content from the ASCO® 2025 Annual Meeting

Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

Oral Presentation Video | Slides | Abstract

* Required field.

© 2025 American Society of Clinical Oncology (ASCO®). All Rights Reserved.